Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealth Net Tryvio Coverage & Prior Auth | OpenPaye…
    Ask Trek AI about this page
    CurrentHealth NetPolicy CP PHAR.676

    Clinical Policy: Aprocitentan (Tryvio)

    Customize your policy alerts

    Sign up for Health Net Policy CP PHAR.676 alerts

    Get alerted when Policy CP PHAR.676 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and prior authorization criteria for aprocitentan (Tryvio) for treatment of hypertension in adults within Health Net/Centene-affiliated plans.

    Policy Summary
    PayerHealth Net
    PolicyAprocitentan (Tryvio) coverage for hypertension
    Policy CodePolicy CP PHAR.676
    Change TypeNo material change
    Effective DateJun 1, 2024
    Next Review DateMay 25, 2025
    Key ActionSubmit prior authorization with office chart notes, recent blood pressure readings, and documentation of adherence to a prior antihypertensive regimen.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Adults ≥18age requirement
    ≥140/90

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    BP threshold
    3+ classesconcurrent regimen
    6 monthsinitial approval
    12.5 mgmax dose

    Coverage Criteria

    inv-01: Initial Therapy

    Covered when ALL of the following are met:

    Initial Approval - Hypertension: 1) Diagnosis of hypertension; 2) Age >= 18 years; 3) Tryvio is prescribed concurrently with an antihypertensive regimen containing three or more drug classes unless clinically significant adverse effects or contraindications to those classes exist (see Appendix B for examples); 4) Documentation of recent (within the last 30 days) blood pressure >= 140/90 mmHg; 5) Member has been adherent for at least the last 4 weeks at up to maximally tolerated doses of an antihypertensive regimen containing at least three different antihypertensive drug classes; 6) Dose does not exceed 12.5 mg (1 tablet) per day; 7) Tryvio is not prescribed concurrently with other endothelin receptor antagonists (e.g., ambrisentan, bosentan, macitentan); Approval duration: 6 months.see text

    Provider must submit documentation (e.g., office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

    inv-18: Initial Approval

    Initial coverage criteria for hypertension:

    Initial Approval: 1) Diagnosis of hypertension; 2) Age >= 18 years; 3) Tryvio prescribed concurrently with an antihypertensive regimen containing three or more drug classes unless contraindicated or not tolerated; 4) Documentation of recent (within the last 30 days) BP >= 140/90 mmHg; 5) Adherence for at least the last 4 weeks at maximally tolerated doses of a regimen containing at least three antihypertensive classes; 6) Dose does not exceed 12.5 mg (1 tablet) per day; 7) Not prescribed concurrently with other endothelin receptor antagonists; Approval duration: 6 months.see text

    See Appendix B for example antihypertensive classes. Providers must submit supporting clinical documentation.

    Non–FDA approved indications are not authorized under this policy unless there is sufficient documentation of efficacy and safety and the request is supported by the applicable off‑label use policy (see CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid) or by the member’s evidence of coverage.

    When state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Refer to the applicable state Medicaid manual for specific coverage rules applicable to Medicaid members.

    Requests for indications that are not FDA‑approved and are not supported by the referenced off‑label use policies (CP.CPA.09, HIM.PA.154, CP.PMN.53) or by the member’s evidence of coverage will be considered not a covered benefit and are not authorized under this policy.

    Initial Therapy — Authorization Requirements

    inv-01: Initial Therapy

    Covered when ALL of the following are met:

    Initial Therapy: 1) Diagnosis of hypertension; 2) Age >= 18 years; 3) Tryvio is prescribed concurrently with an antihypertensive regimen containing three or more drug classes unless clinically significant adverse effects or contraindications to those classes exist; 4) Documentation of recent (within the last 30 days) blood pressure >= 140/90 mmHg; 5) Member has been adherent for at least the last 4 weeks at up to maximally tolerated doses of an antihypertensive regimen containing at least three different antihypertensive drug classes; 6) Dose does not exceed 12.5 mg (1 tablet) per day; 7) Tryvio is not prescribed concurrently with other endothelin receptor antagonists (e.g., ambrisentan, bosentan, macitentan); Approval duration: 6 months.see text

    Provider must submit office chart notes, lab results or other clinical information supporting that member has met all approval criteria.

    inv-06: Blood pressure — required clinical threshold for initiation
    Clinical threshold for initiationRecent (within 30 days) blood pressure ≥ 140/90 mmHg

    Continuation Therapy — Ongoing Authorization

    inv-02: Continuation Therapy

    Covered when ALL of the following are met for continuation:

    Continuation Therapy: 1) Member is currently receiving Tryvio via Centene benefit or previously met initial approval criteria; 2) Member is responding positively to therapy; 3) If request is for a dose increase, new dose does not exceed 12.5 mg (1 tablet) per day; 4) Tryvio is not prescribed concurrently with other endothelin receptor antagonists.see text

    May be subject to continuity of care regulations per state/product; provider should submit supporting clinical documentation (e.g., chart notes, BP measurements).

    inv-19: Continuation

    Criteria for members already receiving therapy:

    Continuation: 1) Member is currently receiving Tryvio via Centene benefit or has previously met initial approval criteria; 2) Member is responding positively to therapy; 3) If request is for a dose increase, new dose does not exceed 12.5 mg (1 tablet) per day; 4) Tryvio is not prescribed concurrently with other endothelin receptor antagonists.

    Provider Actions and Documentation

    Prior Authorization

    Prior authorization required — demonstrate diagnosis and listed clinical criteria

    Prior authorization is required. Requests must demonstrate a diagnosis of hypertension and that all listed clinical criteria are met, including age ≥18 years, recent blood pressure ≥140/90 mmHg, adherence to a prior antihypertensive regimen, concurrent use limits, and dosing limits (≤12.5 mg/day).

    • Diagnosis of hypertension; age ≥18 years
    • Documentation of recent (within 30 days) BP ≥140/90 mmHg
    • Adherence ≥4 weeks to a regimen of at least three antihypertensive drug classes at maximally tolerated doses
    • Dose does not exceed 12.5 mg (1 tablet) per day
    • Not prescribed concurrently with other endothelin receptor antagonists
    Step Therapy

    Step/therapeutic positioning — concurrent 3+ drug classes

    Tryvio must be prescribed concurrently with an antihypertensive regimen containing three or more drug classes unless clinically significant adverse effects or contraindications prevent use of those classes.

    Coding and Clinical Thresholds

    inv-06: Blood pressure — documented BP threshold required for initiation (clinical value)
    Documented BP value requiredRecent (within the last 30 days) blood pressure ≥ 140/90 mmHg
    Supporting documentationOffice chart notes, lab results, or other clinical information showing recent BP measurement and adherence
    Context for measurementBP must be documented as part of meeting initial approval criteria for Tryvio initiation

    Step Therapy Requirements

    StepRequirementNotes
    1Tryvio (aprocitentan) must be prescribed concurrently with an antihypertensive regimen containing three or more drug classesRequirement waived only if clinically significant adverse effects are experienced or all drug classes are contraindicated; see Appendix B for example drug classes
    Documentation of recent (within the last 30 days) blood pressure ≥ 140/90 mmHgProvider must submit office chart notes or other clinical information showing recent BP measurements
    Member has been adherent for at least the last 4 weeks at up to maximally tolerated doses of an antihypertensive regimen containing at least three different antihypertensive drug classesAdherence and prior regimen details should be included in submitted documentation
    Dose limit: does not exceed 12.5 mg (1 tablet) per dayPer product availability: tablet strength 12.5 mg

    Quantity Limits

    inv-21: Tryvio (aprocitentan) — quantity/packaging summary (1 tablet; maximum strength info referenced elsewhere)
    Dosage form/packagingTablet
    Quantity limit per day1 tablet per day
    Maximum marketed tablet strength12.5 mg per tablet

    Definitions

    inv-16: Aprocitentan (Tryvio) — Endothelin receptor antagonist (definition/agent key-value)
    Drug classEndothelin receptor antagonist
    Agent name (brand/generic)Tryvio (aprocitentan)
    Indication summaryIndicated for treatment of hypertension in combination with other antihypertensive drugs for adults not adequately controlled on other therapies
    inv-17: Provider relationship — Providers are independent contractors and not agents/employees of the Health Plan
    Provider relationship to Health PlanProviders are independent contractors who exercise independent judgment and are not agents or employees of the Health Plan
    Responsibility noteProviders are solely responsible for medical advice and treatment of members

    Background

    Aprocitentan (Tryvio) is an endothelin receptor antagonist approved to lower blood pressure in adults with hypertension when used in combination with other antihypertensive agents. The product is available as a 12.5 mg tablet and is indicated for adult patients with hypertension inadequately controlled on other therapies.

    Policy Summary
    PayerHealth Net
    PolicyAprocitentan (Tryvio) coverage for hypertension
    Policy CodePolicy CP PHAR.676
    Change TypeNo material change
    Effective DateJun 1, 2024
    Next Review DateMay 25, 2025
    Key ActionSubmit prior authorization with office chart notes, recent blood pressure readings, and documentation of adherence to a prior antihypertensive regimen.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy — Authorization RequirementsContinuation Therapy — Ongoing AuthorizationProvider Actions and DocumentationCoding and Clinical ThresholdsStep Therapy RequirementsQuantity LimitsDefinitionsBackground
    Age requirementAdults ≥ 18 years
    Adherence requirementMember must have been adherent ≥4 weeks to an antihypertensive regimen at maximally tolerated doses
    see text

    Continuity of care provisions may apply in certain states/products; providers must supply documentation supporting continued benefit.

    • Concurrent regimen must include THREE or more antihypertensive drug classes (see Appendix B for examples)
    • Exception allowed if clinically significant adverse effects experienced or all classes are contraindicated
    Step Therapy

    Step therapy — use only with ≥3-class antihypertensive regimen (or documented intolerance)

    Step therapy requirement: Tryvio must be used with an antihypertensive regimen containing ≥3 drug classes, unless the member has documented intolerance or contraindication to those classes.

    • Requirement applies to initiation of Tryvio
    • Documented intolerance or contraindication to the ≥3 drug classes must be provided to support exception
    Documentation Required

    Required documentation — submit chart notes, labs, and clinical information

    Providers must submit supporting clinical documentation with the authorization request, such as office chart notes, laboratory results, or other clinical information showing the member meets all approval criteria.

    • Include recent BP measurements (within 30 days)
    • Include evidence of adherence to prior antihypertensive therapy for at least 4 weeks
    • Include medication history showing concurrent use of required antihypertensive classes
    Denial Risk

    Denial risk — insufficient documentation may trigger denial

    Insufficient or missing clinical documentation (for example, absence of recent BP readings, adherence evidence, or prior medication trials) may result in denial of the request.

    • Recent BP readings within 30 days must be provided
    • Evidence of adherence and prior regimen trials must be documented
    Note

    Prior authorization process not specified in these sections

    The policy text establishes coverage rules but the cited sections do not specify separate prior authorization procedures beyond the coverage criteria requirements.

    • Coverage criteria are detailed in the policy, but prior authorization process steps are not specified in these chunks
    Note

    Proprietary policy — unauthorized use prohibited

    This clinical policy is the property of the Health Plan; unauthorized copying, use, or distribution of the policy or its contents is strictly prohibited and providers, members, and representatives are bound by its terms.

    • Providers, members, and representatives are bound to the policy terms when providing services or submitting claims
    Note

    Professional judgment reminder — policy is informational, not prescriptive

    This clinical policy is informational and does not replace professional medical judgment; providers remain responsible for diagnosis and treatment decisions.

    • Policy is not intended to dictate how providers practice medicine
    • Providers are expected to exercise independent professional medical judgment
    Policy intentThis clinical policy is informational and is not intended to dictate how providers practice medicine